Shares of Forte Biosciences, Inc. (FBRX) fell more than 80 percent as the company reported on Thursday that the topline data from its phase 2 trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint. Based on the data, the company said it will not continue to advance FB-401.
FB-401 was the lead product of this clinical-stage biopharmaceutical company focused on dermatology. The company started the multi-center, placebo-controlled clinical trial of FB-401 in September 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.